Salix Pharmaceuticals, Ltd. acquires, develops, and markets prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. The company’s marketing products include XIFAXAN tablets for the treatment of patients with travelers’ diarrhea, as well as for overt hepatic encephalopathy; MOVIPREP, OSMOPREP, and VISICOL, which are used for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; APRISO for the maintenance of remission of ulcerative colitis; SOLESTA for the treatment of fecal incontinence; DEFLUX for the treatment of vesicoureteral reflux; and METOZOLV ODT for the treatment of symptomatic documented gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy, as well as relief of symptoms of acute and recurrent diabetic gastroparesis. Its products also comprise AZASAN Azathioprine Tablets, which are used as an adjunct for the prevention of rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL for the treatment of hypertension and also as adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney diseases; and COLAZAL to treat mildly to moderately active ulcerative colitis. Further, it develops products to treat irritable bowel syndrome, HIV-associated diarrhea, ulcerative colitis and proctitis, and Opioid induced constipation. The company was founded in 1989 and is headquartered in Raleigh, North Carolina.

Key Statistics